PIN6 EPIDEMIOLOGIC AND ECONOMIC IMPACT OF ROUTINE VACCINATION OF INFANTS AGAINST ROTAVIRUS GASTROENTERITIS IN GERMANY: A PRELIMINARY ANALYSIS  by Hammerschmidt, T et al.
PIN6
EPIDEMIOLOGIC AND ECONOMIC IMPACT OF ROUTINE
VACCINATION OF INFANTS AGAINST ROTAVIRUS
GASTROENTERITIS IN GERMANY:A PRELIMINARY ANALYSIS
Hammerschmidt T1, Forster J2, Huppertz HI3, Heininger U4,
Roos R5, Standaert BA6
1GlaxoSmithKline, Munich, Germany, 2St. Josefs-Hospital, Freiburg,
Germany, 3Prof.-Hess Children’s Hospital, Bremen, Germany,
4University-Children’s Hospital Basel, Basle, Switzerland,
5Hospital Munich-Harlaching, Munich, Germany, 6GlaxoSmithKline
Biologicals, Rixensart, Belgium
OBJECTIVES: Rotavirus gastroenteritis (RVGE) is among the
most common reasons for physician consultations during the ﬁrst
year’s of life. RVGE can be prevented by vaccination. The objec-
tive was to analyse the clinical and economic impact of universal
rotavirus vaccination of infants in Germany. METHODS: A
Markov model was developed and calibrated to reﬂect observed
epidemiological data. In the model, a cohort of 670,000 new-
borns was followed over ﬁve years. Routine vaccination with the
oral vaccine RotarixTM was compared with no vaccination.
Efﬁcacy derived from a European phase-III trial (eTrack102247/
NCT140686) demonstrated 87% efﬁcacy against RVGE of any
severity, 96% against severe RVGE and 100% against hospitali-
sation due to RVGE. Total costs to society were 432 € per
outpatient, 2,085 € per community-acquired hospitalization, and
478 € for nosocomial RV cases. Utility values were 0.546 for
mild, 0.339 for severe, 0.312 for hospitalized, and 0.501 for
nosocomial cases. Cost/effects were discounted by 4.0%/1.5%.
Sensitivity analyses were conducted on costs 15%, utilities
15%, efﬁcacy (95%CI), discounting and vaccine price (within
pharmacy mark-up differences anticipated with a larger pack-
size). RESULTS: In the cohort, 182,820 community-acquired
cases (140,785 presenting to physicians and of those 33,081 were
hospitalized) and 19,848 nosocomial cases occurred resulting in
costs of 128.2 mio. €. The overall number of cases could be
reduced by 82.0%. Approximately 4 children had to be vacci-
nated to prevent one RV case and 21 children had to be vacci-
nated to prevent one community-acquired, hospitalized case.
Cost-effectiveness was 3,770 € per QALY. Cost/QALY was below
15.000 € for all sensitivity analyses, the cost/QALY being most
sensitive to variations in cost assumptions. At higher costs, lower
vaccine price and without discounting, vaccination was cost-
saving. CONCLUSION: Rotavirus causes a considerable burden
of disease and associated costs. Universal vaccination of infants
is a cost-effective approach to reducing this socio-economic
burden.
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OBJECTIVES: Rotavirus is the most common cause of gastro-
enteritis in young children worldwide, resulting in a high burden
of disease. The objective of this study was to evaluate the effects
of vaccinating infants with a pentavalent rotavirus vaccine,
RotaTeq®, in Germany. METHODS: Using a decision analytic
model a birth cohort of 705,622 newborns was followed from
birth up to 5 years of age. Total societal cost associated with
rotavirus gastroenteritis in this cohort was calculated. Potential
costs and beneﬁts of a universal rotavirus vaccination pro-
gramme were assessed. Input parameters were derived from a
German prospective epidemiological study (“REVEAL study”),
national statistics and published literature. Efﬁcacy of RotaTeq®
(prevention of 86% ofﬁce visits, of 96% hospitalisations) was
based on a large clinical trial (“REST Efﬁcacy Study”, Phase III).
Main outcome measures were cases avoided, total societal direct
and indirect disease costs and vaccination expenditures of
Sickness Funds (administration fees & vaccine costs). Cost per
avoided case was used as a measure of cost-effectiveness. In
addition, the number needed to vaccinate (NNV) was calculated.
RESULTS: A rotavirus vaccination programme with a coverage
rate of 90% would prevent in total about 325,565 cases of
rotavirus infections in Germany (-75%) and the huge burden of
human suffering behind these cases. Total societal costs associ-
ated with paediatric rotavirus gastro-enteritis are estimated at
€119.2 million. The vaccination programme with cost of €117.2
million could reduce the societal disease costs by €91.8 million
(-77%). This leads to costs per hospitalised case avoided of
€1405.70 and a NNV of 35 infants. To avoid 1 general
practitioner/paediatrician case the NNV is 6 with costs per case
prevented of €191.90. CONCLUSION: Implementing a rotavi-
rus vaccination programme in Germany with RotaTeq® will
signiﬁcantly and efﬁciently decrease the morbidity and associated
burden due to rotavirus infections in young children. –2007–>.
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OBJECTIVES: To evaluate the cost-effectiveness of the MF59
adjuvanted inﬂuenza vaccine versus non-adjuvanted vaccine in
the “at risk” adult population (age 18–64) in France. A central
feature of the analysis was the occurrence of antigenic drift and
its effect on vaccination efﬁcacy against inﬂuenza. Antigenic drift
is a mutation in the inﬂuenza virus, so that an immune system
response that combats inﬂuenza one year may not provide com-
plete protection the following year. METHODS: A decision-
analytic model was developed using evidence from clinical
studies to compare relative effectiveness of MF59 adjuvanted
inﬂuenza vaccine and non-adjuvanted vaccine in years when
antigenic drift occurs. Data on the impact on hospitalisations, GP
visits and mortality was taken from a case-control study, with
other resource use parameters and costs from the literature.
The analysis was performed from the payer perspective (direct
medical costs) for “at risk” adults in France. “At risk” is deﬁned
as persons with comorbidities such as diabetes and respiratory
problems who have elevated risk of developing complications.
RESULTS: MF59 adjuvanted inﬂuenza vaccine maintains effec-
tiveness post antigenic drift more than non-adjuvanted vaccines.
It was estimated that in an average year 14% of viral strains drift.
Using this estimate, for an attack rate of inﬂuenza-like illness of
6% and a 3% discount rate, the incremental cost per life year
gained (ICLYG) was €19,358. In a pessimistic scenario where
100% of viral strains drift, the ICLYG was €204. ICLYG was
most sensitive to hospitalisation rate, extent of antigenic drift
and vaccine price. CONCLUSION: The incremental CLYG is
well within acceptable European thresholds. Compared to non-
adjuvanted vaccines, MF59 adjuvanted vaccine can be consid-
ered cost-effective for the “at risk” adult population aged <65
years in France and close to cost-neutral in years when antigenic
drift occurs, protecting better individuals at higher risk of com-
plications and hospitalisation.
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